ArticlePloS one2026
Rifampicin resistance and associated factors of Mycobacterium tuberculosis among pulmonary tuberculosis-suspected patients in the Amhara National Regional State Comprehensive Specialized Hospitals, Ethiopia.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTuberculosis (TB) remains a major public health challenge globally, with drug-resistant strains, particularly rifampicin-resistant Mycobacterium tuberculosis (RR-MTB), which poses serious challenges for treatment and control. Rifampicin resistance is widely recognized as a key surrogate marker for multidrug-resistant MTB and is associated with poor treatment outcomes and increased transmission risk. Ethiopia is among the high-TB-burden countries, and the Amhara National Regional State continues to report significant tuberculosis morbidity and mortality.
objectiveTo assess the prevalence, rifampicin resistance patterns, and associated factors of M. tuberculosis among pulmonary tuberculosis-suspected patients at the Amhara National Regional State Comprehensive Specialized Hospitals, Northwest Ethiopia.
methodsA multicenter prospective cross-sectional study was conducted among pulmonary tuberculosis-suspected patients attending the Comprehensive Specialized Hospitals from April 2023, to May 2025. Socio-demographic and associated factors data were collected using semi-structured questionnaires. Sputum was collected and tested using GeneXpert MTB/RIF assay to detect M. tuberculosis and rifampicin resistance. Data were entered into SPSS version 28 for analysis. Binary logistic regression was applied to assess the relationship between predictors and the prevalence of M. tuberculosis, and rifampicin resistance. Variables with a p-value < 0.05 at 95% confidence interval in multivariable logistic regression were considered statistically significant.
resultsAmong 2548 pulmonary tuberculosis (PTB)-suspected participants, the overall prevalence of M. tuberculosis (MTB) was 150/2548 (5.9%). Rifampicin resistance was detected in 19/150 (12.7%) of MTB-positive cases, urban residents 7/70 (18.6%), and low education (grades 1-4), 3/15 (20.0%). In multivariable logistic regression analysis, rural residence was associated with reduced PTB infection compared with urban residence (AOR: 0.23; 95% CI: 0.06-0.79; p = 0.020). Previous antibiotic use (AOR: 9.17; 95% CI: 2.01-28.14; p = 0.001), HIV-positivity (AOR: 3.73; 95% CI: 2.40-7.78; p = 0.001) and alcohol consumption (AOR: 7.10; 95% CI: 4.99-20.86; p = 0.001) were independently associated with increased MTB infection. Rural residents showed significantly lower odds of rifampicin-resistant MTB compared to urban counterparts (AOR: 0.35, 95% CI: 0.12-0.99, p = 0.048).
conclusionThe prevalence of M. tuberculosis infection and rifampicin resistance remains significant in the study area. The strong association between prior antibiotic use, HIV-positivity and alcohol consumption with M. tuberculosis highlights the need for targeted case-finding, improved diagnosis, rational antibiotic use, and focused health education interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.